Stephen L. Abrams

The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy

Stephen L. Abrams, Linda S. Steelman, John G. Shelton et al. · Cell Cycle · 2010 · 136 citations · Full text

Drug Resistant Cells, Chemoprevention Strategy, Apoptosis +16

Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis

James A. McCubrey, Stephen L. Abrams, Timothy L. Fitzgerald et al. · Advances in Biological Regulation · 2014 · 112 citations

Cancer Research, Health Sciences, Molecular Pathway +10

p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3

William H. Chappell, Brian D. Lehmann, David M. Terrian et al. · Cell Cycle · 2012 · 110 citations · Full text

P53 Transcription Factor, P53 Expression Controls, Urology +12

Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells

Linda S. Steelman, Patrick M. Navolanic, William H. Chappell et al. · Cell Cycle · 2011 · 91 citations · Full text

Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy

Melissa L. Sokolosky, Kristin M. Stadelman, William H. Chappell et al. · Oncotarget · 2011 · 81 citations · Full text

Breast Oncology, Chemoprevention Strategy, Immunology +20